Angiotensin converting enzyme inhibitor potentiates the hypoglycaemic effect of NG-nitro-L-arginine methyl ester (L-NAME) in rats.
Esther Oluwasola AlukoVictor Udo NnaAdesoji Adedipe FasanmadePublished in: Archives of physiology and biochemistry (2020)
The inhibition of renin angiotensin system pathway has been largely documented to be effective in the control of cardiovascular events. The present study investigated the effect of angiotensin converting enzyme (ACE) inhibitor on fasting blood glucose level in hypertension induced by the inhibition of nitric oxide synthase (NOS) in male Wistar rats. Hypertension was induced by the inhibition of NOS using a non-selective NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME). The blockade of NOS resulted in an increase in blood pressure, ACE, angiotensin II and endothelin-1 levels, and a decrease in fasting blood glucose and nitric oxide (NO) levels. The hypertensive rats treated with ACE inhibitor (ramipril) recorded a decrease in blood pressure, ACE, angiotensin II, endothelin-1, NO and fasting blood glucose levels, and an increase in prostacyclin level. In conclusion, ACE inhibitor potentiated the hypoglycaemic effect of NOS inhibitor and this effect is independent of NO and pancreatic insulin release.
Keyphrases
- blood glucose
- angiotensin converting enzyme
- angiotensin ii
- nitric oxide synthase
- nitric oxide
- blood pressure
- glycemic control
- vascular smooth muscle cells
- cardiovascular events
- type diabetes
- hypertensive patients
- hydrogen peroxide
- coronary artery disease
- insulin resistance
- cardiovascular disease
- skeletal muscle
- high resolution
- metabolic syndrome
- atomic force microscopy
- pulmonary arterial hypertension